Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

1. Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials.Food science & nutrition · 2026
   Review
2. Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026
   Article
3. Integrative Bioinformatics Analysis Reveals Potential Target Genes and PTEN Signaling in Breast Cancer and Effect of Zingiber officinale (Ginger) and Allium sativum (Garlic) extract on It.Asian Pacific journal of cancer prevention : APJCP · 2024
   Article
4. The inhibitory effect of trastuzumab on BT474 triple‑positive breast cancer cell viability is reversed by the combination of progesterone and estradiol.Oncology letters · 2024
   Article
5. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
   Article
6. Dual-targeting therapy against HER3/MET in human colorectal cancers.Cancer medicine · 2023
   Article
7. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.Breast cancer research and treatment · 2022
   Article
8. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.BMC cancer · 2022
   Article
9. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.Molecular cancer therapeutics · 2022
   Article
10. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.Journal of hematology & oncology · 2021
    Article
11. Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer.Cancers · 2021
    Review
12. New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer.Geburtshilfe und Frauenheilkunde · 2021
    Article
13. Arctigenin-mediated cell death of SK-BR-3 cells is caused by HER2 inhibition and autophagy-linked apoptosis.Pharmacological reports : PR · 2021
    Article
14. Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.Breast cancer research and treatment · 2021
    Article
15. Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer.Therapeutic advances in medical oncology · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract